Verastem Oncology

Verastem Oncology is here in front of the steps of the beautiful Philadelphia Museum of Art for the 20th anniversary of the Sandy Sprint Philadelphia! Excited to participate in this day of action to support the mission of the Sandy Rollman Ovarian Cancer Foundation!

We are at the Oncology Nursing Society's 2024 Annual Congress meeting. Stop by our booth #3072 in the Learning Hall to learn about our clinical trials for low-grade serous ovarian cancer (#LGSOC), pancreatic cancer, and lung cancer. #ONSCongress #VerastemOnc #CancerResearch

Join us in welcoming John Hayslip, M.D., as our new Chief Medical Officer. Dr. Hayslip is an accomplished oncologist with deep clinical research, development, and commercialization experience, and will lead our development programs for avutometinib and advance our pipeline assets. Learn more: https://lnkd.in/e_pPYJhK #VerastemOnc 

The KRAS G12D mutation is the most prevalent KRAS mutation across human cancers and currently there are no FDA-approved treatments targeting this mutation. For the first time, along with our partner GenFleet Therapeutics, we will share preclinical data on GFH375/VS-7375, a potent and selective orally bioavailable KRAS G12D (ON/OFF) inhibitor. The preclinical data will include potency, selectivity, anti-tumor efficacy, and bioavailability data. #AACR24 #cancerresearch #VerastemOnc #KRAS Check out all the preclinical data we have at AACR this year: https://lnkd.in/gypX8Vpv

“𝗪𝗲’𝗿𝗲 𝗷𝘂𝘀𝘁 𝗼𝗻𝗲 𝘀𝗺𝗮𝗹𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝗮𝗻𝗱 𝘄𝗲’𝗿𝗲 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘁𝗼 𝗺𝗮𝗸𝗲 𝗮 𝗯𝗶𝗴 𝗶𝗺𝗽𝗮𝗰𝘁.” Our CEO Dan Paterson recently sat down with PharmaVoice to talk about his transition to the CEO role last year and the work we are doing to bring a new treatment option for patients living with a rare cancer called low-grade serous ovarian cancer or LGSOC. As our CEO shared, this rare cancer has not received much attention but at Verastem Oncology we are working to change this by collaborating with people living with LGSOC, researchers, and the patient advocacy community to make a difference. Thanks, Michael Gibney of PharmaVoice, for sharing our journey from innovation to impact. Read the story here: https://bit.ly/43O66Jy   #VerastemOnc #LGSOC #ovariancancer

Tomorrow is #NationalDoctorsDay and we want to share resources from our partner LUNGevity Foundation, tailored to help doctors guide patients with non-small cell lung cancer towards comprehensive biomarker testing and finding an appropriate treatment plan.  Doctors can explore the #NoOneMissed HCP webpage for the latest biomarker testing news, find a guide on discussing this step with patients, and more: no1missed.org/3T8otox #lungcancer #biomarkertesting  Thank you, #doctors! 

Shanta Peinado joined Verastem in 2023 as a Medical Science Liaison (MSL) and works to build impactful relationships with key opinion leaders and providing crucial support to our clinical trials through educational initiatives and outreach efforts. What Shanta loves most about her job is the opportunity to engage with leading oncology experts to help identify potential treatment options for patients. Throughout Shanta’s journey, she has gained a deep appreciation for the drive, dedication, and hard work of a small biopharma company striving to make a difference in the oncology treatment landscape. #VerastemOnc #EmployeeSpotlight

While the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer may be over, the findings from our #LGSOCPatientImpactSurvey with patient advocates and community medical leaders remain timely. Patients of low-grade serous ovarian cancer, #LGSOC, face complex challenges extending beyond medical treatment. As highlighted by Nicole Andrews, Board Chair of STAAR Ovarian Cancer, holistic support and bolstering hope for those affected is necessary.

Thank you, Nick Taylor with Fierce Pharma for highlighting the importance of increasing awareness and dialogue around the toll rare cancers like low-grade serous ovarian cancer (#LGSOC) take on patients' social, emotional and mental health.      As evidenced by our recent #LGSOCPatientImpactSurvey created in partnership with patient advocates and medical leaders like Dr. Charlotte Sun and Dr. David Gershenson, continuing the conversation and working towards better outcomes and new treatment options is crucial.     https://bit.ly/3PpTjH0  

Did you know 87% of patients with low-grade serous ovarian cancer or LGSOC recently surveyed reported being afraid to make long-term plans? And 94% of the survey respondents were worried that their LGSOC would return despite treatment. Today, we unveiled these results from our LGSOC Patient Impact Survey that highlighted the significant negative impact that this rare ovarian cancer has on many aspects of patients' lives. The global survey was developed in partnership with patient advocates and community medical leaders and was presented at the Society of Gynecologic Oncology's Annual Meeting on Women’s Cancer. Read the press release to learn more: https://bit.ly/3IIgM2m #SGOmtg #PowerofSharedPurpose #LGSOC #ovariancancer #LGSOCPatientImpactSurvey